Appendix 4D & Half Year Financial Report
Filed with ASX · · 26 pages · English
In the deck
Story so far
Earlier from Cogstate
- Global Alzheimer Platform Foundation Selects Cogstate
- Interim Business Update
- Cogstate cleared by FDA to start marketing Cognigram in U.S.
- FY17 Earnings Update
- Cogstate selected as preferred provider for Lilly
Later from Cogstate
- S&P DJ Indices Announces March Quarterly Rebalance
- Cogstate Establishes Rare Disease and Pediatric Expertise
- Business Update & Appendix 4C
- Cogstate announces European approval for Cognigram
- AD trial discontinued - limited CGS impact
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate